Table 2.

Comparison of Treat-to-Target in Gout Patients Enrolled in E-visits Compared to Historical Controls

	E-visit Program (n=62)	Controls (n=62)	P- value
Mean number of office visits in 6 months*	0.8 (0.8)	1.1 (1.0)	0.08
Mean number of E-visits in 6 months*	1.6 (1.5)	N/A	N/A
Completed at least one E-visit (n,%)	43 (69.4)	N/A	N/A
Mean initial serum urate (mg/dL)*	8.3 (1.5)	8.2 (1.8)	0.73
Mean number of follow up serum urate	1.8 (1.4)	1.3 (1.3)	0.03
checks in study period*
Mean serum urate at 6 months (mg/dL)*	5.5 (1.5)	6.7 (1.6)	<0.01
Allopurinol (n,%)	56 (90.3)	55 (88.7)	0.77
Febuxostat (n,%)	4 (6.5)	5 (8.1)	0.73
Probenecid (n,%)	0	1 (1.6)	0.32
Pegloticase (n,%)	1 (1.6)	0	0.32
Mean allopurinol dose at 6 months (mg)*	273.5 (97.6)	261.7 (109.8)	0.56
Dose change/escalation over 6 months (n,%)**	45 (72.6)	43 (70.5)	0.70
Achieved goal serum urate (n,%)***	37 (63.8)	21 (33.9)	<0.01

^*All mean values are reported with standard deviation in parentheses unless otherwise indicated

^**Includes change in dose of ULT or switch to another medication

^***Goal serum urate defined as <6 mg/dL

N/A: not applicable